Meningococcal groups C and y and haemophilus b tetanus toxoid conjugate vaccine (HibMenCY-TT; MenHibrix®): A review

Drugs

Volumn 73, Issue 7, 2013, Pages 703-713

  Perry, Caroline M ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CHICKENPOX VACCINE; DIPHTHERIA PERTUSSIS TETANUS HEPATITIS B VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; MEASLES MUMPS RUBELLA VACCINE; MENHIBRIX; MENINGOCOCCUS VACCINE; MMR; OUTER MEMBRANE PROTEIN; PALIVIZUMAB; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ACTIVE IMMUNIZATION; ANTIBODY RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFANT; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AGE FACTORS; HAEMOPHILUS INFLUENZAE TYPE B; HAEMOPHILUS VACCINES; HUMANS; POLYSACCHARIDES, BACTERIAL; TETANUS TOXOID; VACCINES, COMBINED;

HAEMOPHILUS; NEISSERIA MENINGITIDIS; NEISSERIA MENINGITIDIS SEROGROUP C; POLIOVIRUS; RUBELLA; STREPTOCOCCUS PNEUMONIAE;

EID: 84878656101     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-013-0048-9     Document Type: Review

References (40)

1. World Health Organization. New and under-utilized vaccines implementation (NUVI). 2012. http://www.who.int/nuvi/meningitis/en/index.html. Accessed 22 Mar 2013.
2. World Health Organization. Bacterial meningitis (including Haemophilus influenzae type b (Hib), Neisseria meningitidis, and Streptococcus pneumoniae). 2012. http://www.who.int/immunization-monitoring/diseases/meningitis- surveillance/en. Accessed 22 Mar 2013.
3. Girard MP, Preziosi MP, Aguado MT, et al. A review of vaccine research and development: meningococcal disease. Vaccine. 2006;24(22):4692-700.
4. Brooks R, Woods C, Benjamin D Jr, et al. Increased case-fatality rate associated with outbreaks of Neisseria meningitidis infection, compared with sporadic meningococcal disease, in the United States, 1994-2002. Clin Infect Dis. 2006;43(1):49-54.
5. Al-Tawfiq JA, Clark TA, Memish ZA. Meningococcal disease: the organism, clinical presentation, and worldwide epidemiology. J Travel Med. 2010;17(Suppl):3-8.
6. van Deuren M, Brandtzaeg P, van Der Meer J, et al. Update on meningococcal disease with emphasis on pathogenesis and clinical management. Clin Microbiol Rev. 2000;13(1):144-66.
7. Bryant KA, Marshall GS. Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine for infants and toddlers. Expert Rev Vaccines. 2011;10(7):941-50.
8. Khatami A, Pollard AJ. The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 2010;9(3):285-98.
9. Cohn AC, MacNeil JR, Harrison LH. Changes in Neisseria meningitidis disease epidemiology in the United States 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis. 2010;50(2):184-91.
10. Harrison LH, Pelton SI, Wilder-Smith A, et al. The global meningococcal initiative: recommendations for reducing the global burden of meningococcal disease. Vaccine. 2011;29(18):3363-71.
11. Harrison LH. Epidemiological profile of meningococcal disease in the United States. Clin Infect Dis. 2010;50(2):S37-44.
12. Hausdorff WP, Hajjeh R, Al-Mazrou A, et al. The epidemiology of pneumococcal, meningococcal, and Haemophilus disease in the Middle East and North Africa (MENA) region - current status and needs. Vaccine. 2007;25(11):1935-44.
13. Harrison LH, Trotter CL, Ramsay ME. Global epidemiology of meningococcal disease. Vaccine. 2009;27(Suppl. 2):B51-63.
14. GlaxoSmithKline. GSK Receives FDA Approval for MenHibrix. 2012. http://us.gsk.com/html/media-news/pressreleases/2012/2012-pressrelease-1134018. htm. Accessed 22 Mar 2013.
15. Marshall GS. Perspectives on immunization. J Manag Care Med. 2012;15(3):5-10.
16. Richmond P, Kaczmarski E, Borrow R, et al. Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 2000;181(2):761-4.
17. Harrison LH. Prospects for vaccine prevention of meningococcal infection. Clin Microbiol Rev. 2006;19(1):142-64.
18. Granoff DM, Gupta RK, Belshe RB, et al. Induction of immunologic refractoriness in adults by meningococcal C polysaccharide vaccination. J Infect Dis. 1998;178(3):870-4.
19. Broker M, Veitch K. Quadrivalent meningococcal vaccines: hyporesponsiveness as an important consideration when choosing between the use of conjugate vaccine or polysaccharide vaccine. Travel Med Infect Dis. 2010;8(1):47-50.
20. Miller JM, Mesaros N, Van Der Wielen M, et al. Conjugate meningococcal vaccines development: GSK biologicals experience. Adv Prev Med. 2011;Article ID 846756.
21. Centers for Disease Control and Prevention (CDC). Updated recommendations for the use of meningococcal conjugate vaccines - Advisory Committee on Immunization Practices (ACIP), 2010. Morbidity and Mortality Weekly Report (MMWR). 2011;60:72-6.
22. TM). Drugs. 2012;72(18):2407-30.
23. Bryant KA, Marshall GS, Marchant CD, et al. Immunogenicity and safety of H influenzae type b-N meningitidis C/Y conjugate vaccine in infants. Pediatrics. 2011;127(6):e1375-85.
24. GlaxoSmithKline. US prescribing information for MenHibrix (Meningococcal Groups C and Y and Haemophilus b Tetanus Toxoid Conjugate Vaccine) 2012. http://us.gsk.com/products/assets/us-menhibrix.pdf. Accessed 22 Mar 2013.
25. Centers for Disease Control and Prevention (CDC). Infant meningococcal vaccination: Advisory Committee on Immunization Practices (ACIP) recommendations and rationale. MMWR Morb Mortal Wkly Rep. 2013;62:52-4.
26. Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp Med. 1969;129:1307-26.
27. Robbins JB, Parke JC, Schneerson R, et al. Quantitative measurement of "natural" and immunization-induced Haemophilus influenzae type b capsular polysaccharide antibodies. Pediatr Res. 1973;7:103-10.
28. Peltola H, Käythy H, Sivonen A, et al. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field study of 100,000 vaccinees 3 months to 5 years of age in Finland. Pediatrics. 1977;60:730-7.
29. Anderson P. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1984;149:1034-5.
30. Käythy H, Peltola H, Karanko V, et al. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100.
31. Nolan T, Lambert S, Roberton D, et al. A novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y-tetanus-toxoid conjugate vaccine is immunogenic and induces immune memory when co-administered with DTPa-HBV-IPV and conjugate pneumococcal vaccines in infants. Vaccine. 2007;25(51):8487-99.
32. Nolan T, Richmond P, Marshall H, et al. Immunogenicity and safety of an investigational combined haemophilus influenzae type B-Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine. Pediatr Infect Dis J. 2011;30(3):190-6.
33. Habermehl P, Leroux-Roels G, Sanger R, et al. Combined Haemophilus influenzae type b and Neisseria meningitidis serogroup C (HibMenC) or serogroup C and Y-tetanus toxoid conjugate (and HibMenCY) vaccines are well-tolerated and immunogenic when administered according to the 2, 3, 4 months schedule with a fourth dose at 12-18 months of age. Hum. 2010;6(8):640-51.
34. Marchant CD, Miller JM, Marshall GS, et al. Randomized trial to assess immunogenicity and safety of Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine in infants. Pediatr Infect Dis J. 2010;29(1):48-52.
35. Marshall GS, Marchant CD, Blatter M, et al. Immune response and one-year antibody persistence after a fourth dose of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine (HibMenCY) at 12 to 15 months of age. Pediatr Infect Dis J. 2010;29(5):469-71.
36. Marshall GS, Mesaros N, Aris E, et al. Persistence of immunity three years after an investigational haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y tetanus toxoid (HibMenCY-TT) conjugate vaccine (abstract no. 25219). In: Proceedings of the 45th National Immunization Conference, Washington, DC; 28-31 Mar 2011.
37. Marshall G, Blatter M, Marchant C, et al. Antibody persistence for up to 5 years after a fourth dose of Haemophilus influenzae type B and Neisseria Meningitidis serogroups C and Y-Tetanus Toxoid conjugate vaccine (Hibmency-TT) given at 12-15 months. Pediatr Infect Dis J. 2013. doi: 10.1097/INF. 0b013e3182840e35.
38. Marshall GS, Marchant CD, Blatter M, et al. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States. Human Vaccines. 2011;7(2):258-64.
39. Bryant KA, McVernon J, Marchant CD, et al. Immunogenicity and safety of measles-mumps-rubella and varicella vaccines coadminstered with a fourth dose of Haemophilus influenzae type b and Neisseria meningitidis subgroups C and T-tetanus toxoid conjugate vaccine in toddlers. Human Vaccines Immunother. 2012;8(8):1036-41.
40. Rinderknecht S, Bryant K, Nolan T, et al. The safety profile of Haemophilus influenzae type b-Neisseria meningitidis serogroups C and Y tetanus toxoid conjugate vaccine (HibMenCY). Human Vaccines Immunother. 2012;8(3):294-301.